nodes	percent_of_prediction	percent_of_DWPC	metapath
Ezogabine—Skin discolouration—Epirubicin—ovarian cancer	0.00311	0.00352	CcSEcCtD
Ezogabine—Influenza—Paclitaxel—ovarian cancer	0.00309	0.00349	CcSEcCtD
Ezogabine—Dysphagia—Paclitaxel—ovarian cancer	0.00309	0.00349	CcSEcCtD
Ezogabine—Infection—Topotecan—ovarian cancer	0.00303	0.00342	CcSEcCtD
Ezogabine—Dyspepsia—Chlorambucil—ovarian cancer	0.00302	0.00341	CcSEcCtD
Ezogabine—Nervous system disorder—Topotecan—ovarian cancer	0.00299	0.00338	CcSEcCtD
Ezogabine—Thrombocytopenia—Topotecan—ovarian cancer	0.00299	0.00337	CcSEcCtD
Ezogabine—Dysarthria—Epirubicin—ovarian cancer	0.00297	0.00336	CcSEcCtD
Ezogabine—Infection—Melphalan—ovarian cancer	0.00297	0.00335	CcSEcCtD
Ezogabine—Ill-defined disorder—Vinorelbine—ovarian cancer	0.00297	0.00335	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00296	0.00334	CcSEcCtD
Ezogabine—Fatigue—Chlorambucil—ovarian cancer	0.00295	0.00334	CcSEcCtD
Ezogabine—Hyperhidrosis—Topotecan—ovarian cancer	0.00295	0.00333	CcSEcCtD
Ezogabine—Thrombocytopenia—Melphalan—ovarian cancer	0.00292	0.0033	CcSEcCtD
Ezogabine—Neutropenia—Paclitaxel—ovarian cancer	0.00289	0.00326	CcSEcCtD
Ezogabine—Dysuria—Paclitaxel—ovarian cancer	0.00289	0.00326	CcSEcCtD
Ezogabine—Malaise—Vinorelbine—ovarian cancer	0.00288	0.00326	CcSEcCtD
Ezogabine—Gait disturbance—Epirubicin—ovarian cancer	0.00288	0.00326	CcSEcCtD
Ezogabine—Skin discolouration—Doxorubicin—ovarian cancer	0.00288	0.00326	CcSEcCtD
Ezogabine—Vertigo—Vinorelbine—ovarian cancer	0.00287	0.00325	CcSEcCtD
Ezogabine—Coordination abnormal—Epirubicin—ovarian cancer	0.00286	0.00324	CcSEcCtD
Ezogabine—Leukopenia—Vinorelbine—ovarian cancer	0.00286	0.00323	CcSEcCtD
Ezogabine—Feeling abnormal—Chlorambucil—ovarian cancer	0.00282	0.00319	CcSEcCtD
Ezogabine—Weight increased—Paclitaxel—ovarian cancer	0.00281	0.00317	CcSEcCtD
Ezogabine—Liver function test abnormal—Docetaxel—ovarian cancer	0.00279	0.00316	CcSEcCtD
Ezogabine—Infestation NOS—Paclitaxel—ovarian cancer	0.00275	0.00311	CcSEcCtD
Ezogabine—Infestation—Paclitaxel—ovarian cancer	0.00275	0.00311	CcSEcCtD
Ezogabine—Dysarthria—Doxorubicin—ovarian cancer	0.00275	0.00311	CcSEcCtD
Ezogabine—Paraesthesia—Topotecan—ovarian cancer	0.00274	0.00309	CcSEcCtD
Ezogabine—Dyspnoea—Topotecan—ovarian cancer	0.00272	0.00307	CcSEcCtD
Ezogabine—Discomfort—Vinorelbine—ovarian cancer	0.00269	0.00304	CcSEcCtD
Ezogabine—Dyspepsia—Topotecan—ovarian cancer	0.00268	0.00303	CcSEcCtD
Ezogabine—Paraesthesia—Melphalan—ovarian cancer	0.00268	0.00303	CcSEcCtD
Ezogabine—Gait disturbance—Doxorubicin—ovarian cancer	0.00267	0.00301	CcSEcCtD
Ezogabine—Dyspnoea—Melphalan—ovarian cancer	0.00266	0.00301	CcSEcCtD
Ezogabine—Coordination abnormal—Doxorubicin—ovarian cancer	0.00265	0.00299	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00263	0.00298	CcSEcCtD
Ezogabine—Fatigue—Topotecan—ovarian cancer	0.00263	0.00297	CcSEcCtD
Ezogabine—Dyspepsia—Melphalan—ovarian cancer	0.00263	0.00297	CcSEcCtD
Ezogabine—Haematuria—Paclitaxel—ovarian cancer	0.00262	0.00296	CcSEcCtD
Ezogabine—Dysphagia—Docetaxel—ovarian cancer	0.00262	0.00296	CcSEcCtD
Ezogabine—Constipation—Topotecan—ovarian cancer	0.00261	0.00295	CcSEcCtD
Ezogabine—Hepatobiliary disease—Paclitaxel—ovarian cancer	0.0026	0.00294	CcSEcCtD
Ezogabine—Infection—Vinorelbine—ovarian cancer	0.00259	0.00293	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00258	0.00291	CcSEcCtD
Ezogabine—Fatigue—Melphalan—ovarian cancer	0.00257	0.00291	CcSEcCtD
Ezogabine—Coma—Epirubicin—ovarian cancer	0.00257	0.0029	CcSEcCtD
Ezogabine—Nervous system disorder—Vinorelbine—ovarian cancer	0.00256	0.00289	CcSEcCtD
Ezogabine—Thrombocytopenia—Vinorelbine—ovarian cancer	0.00255	0.00289	CcSEcCtD
Ezogabine—Feeling abnormal—Topotecan—ovarian cancer	0.00251	0.00284	CcSEcCtD
Ezogabine—Asthenia—Chlorambucil—ovarian cancer	0.00246	0.00278	CcSEcCtD
Ezogabine—Neutropenia—Docetaxel—ovarian cancer	0.00245	0.00276	CcSEcCtD
Ezogabine—Urinary tract disorder—Paclitaxel—ovarian cancer	0.00244	0.00276	CcSEcCtD
Ezogabine—Oedema peripheral—Paclitaxel—ovarian cancer	0.00243	0.00275	CcSEcCtD
Ezogabine—Urethral disorder—Paclitaxel—ovarian cancer	0.00242	0.00274	CcSEcCtD
Ezogabine—Weight increased—Docetaxel—ovarian cancer	0.00238	0.00269	CcSEcCtD
Ezogabine—Visual impairment—Paclitaxel—ovarian cancer	0.00238	0.00269	CcSEcCtD
Ezogabine—Coma—Doxorubicin—ovarian cancer	0.00238	0.00269	CcSEcCtD
Ezogabine—Paraesthesia—Vinorelbine—ovarian cancer	0.00234	0.00265	CcSEcCtD
Ezogabine—Infestation NOS—Docetaxel—ovarian cancer	0.00233	0.00264	CcSEcCtD
Ezogabine—Infestation—Docetaxel—ovarian cancer	0.00233	0.00264	CcSEcCtD
Ezogabine—Dyspnoea—Vinorelbine—ovarian cancer	0.00233	0.00263	CcSEcCtD
Ezogabine—Eye disorder—Paclitaxel—ovarian cancer	0.00231	0.00261	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00225	0.00255	CcSEcCtD
Ezogabine—Fatigue—Vinorelbine—ovarian cancer	0.00225	0.00254	CcSEcCtD
Ezogabine—Constipation—Vinorelbine—ovarian cancer	0.00223	0.00252	CcSEcCtD
Ezogabine—Hepatobiliary disease—Docetaxel—ovarian cancer	0.00221	0.00249	CcSEcCtD
Ezogabine—Asthenia—Topotecan—ovarian cancer	0.00219	0.00247	CcSEcCtD
Ezogabine—Alopecia—Paclitaxel—ovarian cancer	0.00218	0.00247	CcSEcCtD
Ezogabine—Increased appetite—Epirubicin—ovarian cancer	0.00217	0.00246	CcSEcCtD
Ezogabine—Mental disorder—Paclitaxel—ovarian cancer	0.00216	0.00245	CcSEcCtD
Ezogabine—Malnutrition—Paclitaxel—ovarian cancer	0.00215	0.00243	CcSEcCtD
Ezogabine—Feeling abnormal—Vinorelbine—ovarian cancer	0.00215	0.00243	CcSEcCtD
Ezogabine—Asthenia—Melphalan—ovarian cancer	0.00214	0.00242	CcSEcCtD
Ezogabine—Urinary tract disorder—Docetaxel—ovarian cancer	0.00207	0.00234	CcSEcCtD
Ezogabine—Muscle spasms—Paclitaxel—ovarian cancer	0.00207	0.00234	CcSEcCtD
Ezogabine—Oedema peripheral—Docetaxel—ovarian cancer	0.00206	0.00233	CcSEcCtD
Ezogabine—Urethral disorder—Docetaxel—ovarian cancer	0.00205	0.00232	CcSEcCtD
Ezogabine—Osteoarthritis—Epirubicin—ovarian cancer	0.00204	0.00231	CcSEcCtD
Ezogabine—Diplopia—Epirubicin—ovarian cancer	0.00204	0.00231	CcSEcCtD
Ezogabine—Nausea—Chlorambucil—ovarian cancer	0.00203	0.0023	CcSEcCtD
Ezogabine—Vision blurred—Paclitaxel—ovarian cancer	0.00203	0.00229	CcSEcCtD
Ezogabine—Visual impairment—Docetaxel—ovarian cancer	0.00202	0.00228	CcSEcCtD
Ezogabine—Dizziness—Topotecan—ovarian cancer	0.00202	0.00228	CcSEcCtD
Ezogabine—Tremor—Paclitaxel—ovarian cancer	0.00201	0.00228	CcSEcCtD
Ezogabine—Increased appetite—Doxorubicin—ovarian cancer	0.00201	0.00227	CcSEcCtD
Ezogabine—Ill-defined disorder—Paclitaxel—ovarian cancer	0.00199	0.00225	CcSEcCtD
Ezogabine—Eye disorder—Docetaxel—ovarian cancer	0.00196	0.00221	CcSEcCtD
Ezogabine—Malaise—Paclitaxel—ovarian cancer	0.00194	0.00219	CcSEcCtD
Ezogabine—Vertigo—Paclitaxel—ovarian cancer	0.00193	0.00218	CcSEcCtD
Ezogabine—Syncope—Paclitaxel—ovarian cancer	0.00193	0.00218	CcSEcCtD
Ezogabine—Leukopenia—Paclitaxel—ovarian cancer	0.00192	0.00218	CcSEcCtD
Ezogabine—Rash—Topotecan—ovarian cancer	0.00192	0.00217	CcSEcCtD
Ezogabine—Dermatitis—Topotecan—ovarian cancer	0.00192	0.00217	CcSEcCtD
Ezogabine—Loss of consciousness—Paclitaxel—ovarian cancer	0.00189	0.00214	CcSEcCtD
Ezogabine—Osteoarthritis—Doxorubicin—ovarian cancer	0.00189	0.00213	CcSEcCtD
Ezogabine—Diplopia—Doxorubicin—ovarian cancer	0.00189	0.00213	CcSEcCtD
Ezogabine—Liver function test abnormal—Epirubicin—ovarian cancer	0.00188	0.00213	CcSEcCtD
Ezogabine—Rash—Melphalan—ovarian cancer	0.00188	0.00213	CcSEcCtD
Ezogabine—Dermatitis—Melphalan—ovarian cancer	0.00188	0.00213	CcSEcCtD
Ezogabine—Asthenia—Vinorelbine—ovarian cancer	0.00187	0.00212	CcSEcCtD
Ezogabine—Alopecia—Docetaxel—ovarian cancer	0.00185	0.00209	CcSEcCtD
Ezogabine—Mental disorder—Docetaxel—ovarian cancer	0.00183	0.00207	CcSEcCtD
Ezogabine—Anxiety—Paclitaxel—ovarian cancer	0.00182	0.00206	CcSEcCtD
Ezogabine—Malnutrition—Docetaxel—ovarian cancer	0.00182	0.00206	CcSEcCtD
Ezogabine—Nausea—Topotecan—ovarian cancer	0.00181	0.00205	CcSEcCtD
Ezogabine—Discomfort—Paclitaxel—ovarian cancer	0.00181	0.00204	CcSEcCtD
Ezogabine—Dry mouth—Paclitaxel—ovarian cancer	0.00179	0.00202	CcSEcCtD
Ezogabine—Nausea—Melphalan—ovarian cancer	0.00177	0.002	CcSEcCtD
Ezogabine—Confusional state—Paclitaxel—ovarian cancer	0.00177	0.002	CcSEcCtD
Ezogabine—Dysphagia—Epirubicin—ovarian cancer	0.00176	0.00199	CcSEcCtD
Ezogabine—Influenza—Epirubicin—ovarian cancer	0.00176	0.00199	CcSEcCtD
Ezogabine—Muscle spasms—Docetaxel—ovarian cancer	0.00175	0.00198	CcSEcCtD
Ezogabine—Liver function test abnormal—Doxorubicin—ovarian cancer	0.00174	0.00197	CcSEcCtD
Ezogabine—Infection—Paclitaxel—ovarian cancer	0.00174	0.00197	CcSEcCtD
Ezogabine—KCNQ5—female reproductive system—ovarian cancer	0.00173	0.137	CbGeAlD
Ezogabine—Shock—Paclitaxel—ovarian cancer	0.00173	0.00195	CcSEcCtD
Ezogabine—Dizziness—Vinorelbine—ovarian cancer	0.00173	0.00195	CcSEcCtD
Ezogabine—Nervous system disorder—Paclitaxel—ovarian cancer	0.00172	0.00194	CcSEcCtD
Ezogabine—Thrombocytopenia—Paclitaxel—ovarian cancer	0.00172	0.00194	CcSEcCtD
Ezogabine—Hyperhidrosis—Paclitaxel—ovarian cancer	0.0017	0.00192	CcSEcCtD
Ezogabine—Neutropenia—Epirubicin—ovarian cancer	0.00165	0.00186	CcSEcCtD
Ezogabine—Dysuria—Epirubicin—ovarian cancer	0.00165	0.00186	CcSEcCtD
Ezogabine—Rash—Vinorelbine—ovarian cancer	0.00164	0.00186	CcSEcCtD
Ezogabine—Dermatitis—Vinorelbine—ovarian cancer	0.00164	0.00186	CcSEcCtD
Ezogabine—Syncope—Docetaxel—ovarian cancer	0.00163	0.00185	CcSEcCtD
Ezogabine—Dysphagia—Doxorubicin—ovarian cancer	0.00163	0.00184	CcSEcCtD
Ezogabine—Influenza—Doxorubicin—ovarian cancer	0.00163	0.00184	CcSEcCtD
Ezogabine—Leukopenia—Docetaxel—ovarian cancer	0.00163	0.00184	CcSEcCtD
Ezogabine—Weight increased—Epirubicin—ovarian cancer	0.00161	0.00181	CcSEcCtD
Ezogabine—Loss of consciousness—Docetaxel—ovarian cancer	0.0016	0.00181	CcSEcCtD
Ezogabine—Paraesthesia—Paclitaxel—ovarian cancer	0.00158	0.00178	CcSEcCtD
Ezogabine—Infestation—Epirubicin—ovarian cancer	0.00157	0.00178	CcSEcCtD
Ezogabine—Infestation NOS—Epirubicin—ovarian cancer	0.00157	0.00178	CcSEcCtD
Ezogabine—Dyspnoea—Paclitaxel—ovarian cancer	0.00156	0.00177	CcSEcCtD
Ezogabine—KCNQ5—vagina—ovarian cancer	0.00156	0.124	CbGeAlD
Ezogabine—Somnolence—Paclitaxel—ovarian cancer	0.00156	0.00176	CcSEcCtD
Ezogabine—Nausea—Vinorelbine—ovarian cancer	0.00155	0.00175	CcSEcCtD
Ezogabine—Dyspepsia—Paclitaxel—ovarian cancer	0.00154	0.00175	CcSEcCtD
Ezogabine—Dysuria—Doxorubicin—ovarian cancer	0.00153	0.00173	CcSEcCtD
Ezogabine—Neutropenia—Doxorubicin—ovarian cancer	0.00153	0.00173	CcSEcCtD
Ezogabine—Dry mouth—Docetaxel—ovarian cancer	0.00152	0.00171	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00151	0.00171	CcSEcCtD
Ezogabine—Fatigue—Paclitaxel—ovarian cancer	0.00151	0.00171	CcSEcCtD
Ezogabine—Constipation—Paclitaxel—ovarian cancer	0.0015	0.0017	CcSEcCtD
Ezogabine—Haematuria—Epirubicin—ovarian cancer	0.0015	0.00169	CcSEcCtD
Ezogabine—Confusional state—Docetaxel—ovarian cancer	0.0015	0.00169	CcSEcCtD
Ezogabine—Hepatobiliary disease—Epirubicin—ovarian cancer	0.00149	0.00168	CcSEcCtD
Ezogabine—Weight increased—Doxorubicin—ovarian cancer	0.00149	0.00168	CcSEcCtD
Ezogabine—Infection—Docetaxel—ovarian cancer	0.00148	0.00167	CcSEcCtD
Ezogabine—Shock—Docetaxel—ovarian cancer	0.00146	0.00165	CcSEcCtD
Ezogabine—Nervous system disorder—Docetaxel—ovarian cancer	0.00146	0.00165	CcSEcCtD
Ezogabine—Thrombocytopenia—Docetaxel—ovarian cancer	0.00146	0.00165	CcSEcCtD
Ezogabine—Infestation NOS—Doxorubicin—ovarian cancer	0.00146	0.00164	CcSEcCtD
Ezogabine—Infestation—Doxorubicin—ovarian cancer	0.00146	0.00164	CcSEcCtD
Ezogabine—Feeling abnormal—Paclitaxel—ovarian cancer	0.00145	0.00163	CcSEcCtD
Ezogabine—KCNQ4—testis—ovarian cancer	0.00143	0.114	CbGeAlD
Ezogabine—KCNQ2—gonad—ovarian cancer	0.00143	0.113	CbGeAlD
Ezogabine—Urinary tract disorder—Epirubicin—ovarian cancer	0.00139	0.00158	CcSEcCtD
Ezogabine—Oedema peripheral—Epirubicin—ovarian cancer	0.00139	0.00157	CcSEcCtD
Ezogabine—Haematuria—Doxorubicin—ovarian cancer	0.00139	0.00157	CcSEcCtD
Ezogabine—KCNQ3—female reproductive system—ovarian cancer	0.00139	0.11	CbGeAlD
Ezogabine—Urethral disorder—Epirubicin—ovarian cancer	0.00138	0.00156	CcSEcCtD
Ezogabine—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.00138	0.00156	CcSEcCtD
Ezogabine—Visual impairment—Epirubicin—ovarian cancer	0.00136	0.00154	CcSEcCtD
Ezogabine—Paraesthesia—Docetaxel—ovarian cancer	0.00134	0.00151	CcSEcCtD
Ezogabine—Dyspnoea—Docetaxel—ovarian cancer	0.00133	0.0015	CcSEcCtD
Ezogabine—Somnolence—Docetaxel—ovarian cancer	0.00132	0.00149	CcSEcCtD
Ezogabine—Eye disorder—Epirubicin—ovarian cancer	0.00132	0.00149	CcSEcCtD
Ezogabine—Dyspepsia—Docetaxel—ovarian cancer	0.00131	0.00148	CcSEcCtD
Ezogabine—Urinary tract disorder—Doxorubicin—ovarian cancer	0.00129	0.00146	CcSEcCtD
Ezogabine—Oedema peripheral—Doxorubicin—ovarian cancer	0.00129	0.00145	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00128	0.00145	CcSEcCtD
Ezogabine—Fatigue—Docetaxel—ovarian cancer	0.00128	0.00145	CcSEcCtD
Ezogabine—Urethral disorder—Doxorubicin—ovarian cancer	0.00128	0.00145	CcSEcCtD
Ezogabine—KCNQ2—female reproductive system—ovarian cancer	0.00128	0.101	CbGeAlD
Ezogabine—Constipation—Docetaxel—ovarian cancer	0.00127	0.00144	CcSEcCtD
Ezogabine—Visual impairment—Doxorubicin—ovarian cancer	0.00126	0.00142	CcSEcCtD
Ezogabine—Asthenia—Paclitaxel—ovarian cancer	0.00126	0.00142	CcSEcCtD
Ezogabine—Alopecia—Epirubicin—ovarian cancer	0.00125	0.00141	CcSEcCtD
Ezogabine—Mental disorder—Epirubicin—ovarian cancer	0.00124	0.0014	CcSEcCtD
Ezogabine—Malnutrition—Epirubicin—ovarian cancer	0.00123	0.00139	CcSEcCtD
Ezogabine—Feeling abnormal—Docetaxel—ovarian cancer	0.00123	0.00139	CcSEcCtD
Ezogabine—Eye disorder—Doxorubicin—ovarian cancer	0.00122	0.00138	CcSEcCtD
Ezogabine—UGT1A1—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.00121	0.0117	CbGpPWpGaD
Ezogabine—UGT1A9—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.00121	0.0117	CbGpPWpGaD
Ezogabine—Muscle spasms—Epirubicin—ovarian cancer	0.00118	0.00134	CcSEcCtD
Ezogabine—KCNQ2—female gonad—ovarian cancer	0.00116	0.0922	CbGeAlD
Ezogabine—Dizziness—Paclitaxel—ovarian cancer	0.00116	0.00131	CcSEcCtD
Ezogabine—Vision blurred—Epirubicin—ovarian cancer	0.00116	0.00131	CcSEcCtD
Ezogabine—Alopecia—Doxorubicin—ovarian cancer	0.00115	0.0013	CcSEcCtD
Ezogabine—Mental disorder—Doxorubicin—ovarian cancer	0.00114	0.00129	CcSEcCtD
Ezogabine—Ill-defined disorder—Epirubicin—ovarian cancer	0.00114	0.00129	CcSEcCtD
Ezogabine—Malnutrition—Doxorubicin—ovarian cancer	0.00114	0.00129	CcSEcCtD
Ezogabine—Malaise—Epirubicin—ovarian cancer	0.00111	0.00125	CcSEcCtD
Ezogabine—Rash—Paclitaxel—ovarian cancer	0.00111	0.00125	CcSEcCtD
Ezogabine—Dermatitis—Paclitaxel—ovarian cancer	0.00111	0.00125	CcSEcCtD
Ezogabine—Vertigo—Epirubicin—ovarian cancer	0.0011	0.00125	CcSEcCtD
Ezogabine—Syncope—Epirubicin—ovarian cancer	0.0011	0.00125	CcSEcCtD
Ezogabine—Leukopenia—Epirubicin—ovarian cancer	0.0011	0.00124	CcSEcCtD
Ezogabine—NAT2—Biological oxidations—CYP1B1—ovarian cancer	0.0011	0.0107	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	0.0011	0.0107	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CYP1B1—ovarian cancer	0.0011	0.0107	CbGpPWpGaD
Ezogabine—Muscle spasms—Doxorubicin—ovarian cancer	0.00109	0.00124	CcSEcCtD
Ezogabine—NAT2—Metapathway biotransformation—CYP1B1—ovarian cancer	0.00108	0.0105	CbGpPWpGaD
Ezogabine—Loss of consciousness—Epirubicin—ovarian cancer	0.00108	0.00122	CcSEcCtD
Ezogabine—Vision blurred—Doxorubicin—ovarian cancer	0.00107	0.00121	CcSEcCtD
Ezogabine—Asthenia—Docetaxel—ovarian cancer	0.00107	0.00121	CcSEcCtD
Ezogabine—Ill-defined disorder—Doxorubicin—ovarian cancer	0.00106	0.00119	CcSEcCtD
Ezogabine—KCNQ3—Developmental Biology—NR5A1—ovarian cancer	0.00105	0.0102	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—NR5A1—ovarian cancer	0.00105	0.0102	CbGpPWpGaD
Ezogabine—Anxiety—Epirubicin—ovarian cancer	0.00104	0.00118	CcSEcCtD
Ezogabine—Nausea—Paclitaxel—ovarian cancer	0.00104	0.00118	CcSEcCtD
Ezogabine—Discomfort—Epirubicin—ovarian cancer	0.00103	0.00117	CcSEcCtD
Ezogabine—KCNQ2—testis—ovarian cancer	0.00103	0.0818	CbGeAlD
Ezogabine—Malaise—Doxorubicin—ovarian cancer	0.00103	0.00116	CcSEcCtD
Ezogabine—Dry mouth—Epirubicin—ovarian cancer	0.00102	0.00116	CcSEcCtD
Ezogabine—Vertigo—Doxorubicin—ovarian cancer	0.00102	0.00115	CcSEcCtD
Ezogabine—Syncope—Doxorubicin—ovarian cancer	0.00102	0.00115	CcSEcCtD
Ezogabine—Leukopenia—Doxorubicin—ovarian cancer	0.00102	0.00115	CcSEcCtD
Ezogabine—Confusional state—Epirubicin—ovarian cancer	0.00101	0.00114	CcSEcCtD
Ezogabine—KCNQ5—lymph node—ovarian cancer	0.00101	0.0803	CbGeAlD
Ezogabine—Loss of consciousness—Doxorubicin—ovarian cancer	0.001	0.00113	CcSEcCtD
Ezogabine—Infection—Epirubicin—ovarian cancer	0.000997	0.00113	CcSEcCtD
Ezogabine—Shock—Epirubicin—ovarian cancer	0.000987	0.00112	CcSEcCtD
Ezogabine—Nervous system disorder—Epirubicin—ovarian cancer	0.000984	0.00111	CcSEcCtD
Ezogabine—Dizziness—Docetaxel—ovarian cancer	0.000983	0.00111	CcSEcCtD
Ezogabine—Thrombocytopenia—Epirubicin—ovarian cancer	0.000982	0.00111	CcSEcCtD
Ezogabine—Hyperhidrosis—Epirubicin—ovarian cancer	0.00097	0.0011	CcSEcCtD
Ezogabine—Anxiety—Doxorubicin—ovarian cancer	0.000965	0.00109	CcSEcCtD
Ezogabine—Discomfort—Doxorubicin—ovarian cancer	0.000957	0.00108	CcSEcCtD
Ezogabine—Dry mouth—Doxorubicin—ovarian cancer	0.000947	0.00107	CcSEcCtD
Ezogabine—Rash—Docetaxel—ovarian cancer	0.000938	0.00106	CcSEcCtD
Ezogabine—Dermatitis—Docetaxel—ovarian cancer	0.000937	0.00106	CcSEcCtD
Ezogabine—Confusional state—Doxorubicin—ovarian cancer	0.000936	0.00106	CcSEcCtD
Ezogabine—CYP2A6—Constitutive Androstane Receptor Pathway—ABCB1—ovarian cancer	0.000929	0.00906	CbGpPWpGaD
Ezogabine—Infection—Doxorubicin—ovarian cancer	0.000922	0.00104	CcSEcCtD
Ezogabine—Shock—Doxorubicin—ovarian cancer	0.000913	0.00103	CcSEcCtD
Ezogabine—Nervous system disorder—Doxorubicin—ovarian cancer	0.00091	0.00103	CcSEcCtD
Ezogabine—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000909	0.00103	CcSEcCtD
Ezogabine—Paraesthesia—Epirubicin—ovarian cancer	0.000901	0.00102	CcSEcCtD
Ezogabine—Hyperhidrosis—Doxorubicin—ovarian cancer	0.000897	0.00101	CcSEcCtD
Ezogabine—Dyspnoea—Epirubicin—ovarian cancer	0.000894	0.00101	CcSEcCtD
Ezogabine—Somnolence—Epirubicin—ovarian cancer	0.000892	0.00101	CcSEcCtD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TYMS—ovarian cancer	0.000891	0.00868	CbGpPWpGaD
Ezogabine—Nausea—Docetaxel—ovarian cancer	0.000883	0.000998	CcSEcCtD
Ezogabine—Dyspepsia—Epirubicin—ovarian cancer	0.000883	0.000998	CcSEcCtD
Ezogabine—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.000866	0.000979	CcSEcCtD
Ezogabine—Fatigue—Epirubicin—ovarian cancer	0.000865	0.000977	CcSEcCtD
Ezogabine—Constipation—Epirubicin—ovarian cancer	0.000858	0.00097	CcSEcCtD
Ezogabine—Paraesthesia—Doxorubicin—ovarian cancer	0.000833	0.000942	CcSEcCtD
Ezogabine—Dyspnoea—Doxorubicin—ovarian cancer	0.000827	0.000935	CcSEcCtD
Ezogabine—Feeling abnormal—Epirubicin—ovarian cancer	0.000827	0.000934	CcSEcCtD
Ezogabine—Somnolence—Doxorubicin—ovarian cancer	0.000825	0.000933	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—SLC5A5—ovarian cancer	0.000817	0.00796	CbGpPWpGaD
Ezogabine—Dyspepsia—Doxorubicin—ovarian cancer	0.000817	0.000923	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	0.000814	0.00793	CbGpPWpGaD
Ezogabine—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000801	0.000906	CcSEcCtD
Ezogabine—Fatigue—Doxorubicin—ovarian cancer	0.0008	0.000904	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	0.000796	0.00776	CbGpPWpGaD
Ezogabine—Constipation—Doxorubicin—ovarian cancer	0.000794	0.000897	CcSEcCtD
Ezogabine—UGT1A4—NRF2 pathway—SLC2A1—ovarian cancer	0.000789	0.00769	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HNF1B—ovarian cancer	0.000771	0.00751	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—HNF1B—ovarian cancer	0.000771	0.00751	CbGpPWpGaD
Ezogabine—Feeling abnormal—Doxorubicin—ovarian cancer	0.000765	0.000864	CcSEcCtD
Ezogabine—UGT1A9—PPARA activates gene expression—YAP1—ovarian cancer	0.000734	0.00715	CbGpPWpGaD
Ezogabine—Asthenia—Epirubicin—ovarian cancer	0.00072	0.000813	CcSEcCtD
Ezogabine—UGT1A9—Regulation of lipid metabolism by Peroxisome proliferator-activated receptor alpha (PPARalpha)—YAP1—ovarian cancer	0.000719	0.007	CbGpPWpGaD
Ezogabine—UGT1A9—PPAR Alpha Pathway—CCND1—ovarian cancer	0.000704	0.00686	CbGpPWpGaD
Ezogabine—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—ovarian cancer	0.000698	0.0068	CbGpPWpGaD
Ezogabine—CYP2A6—Cytochrome P450 - arranged by substrate type—CYP1B1—ovarian cancer	0.000683	0.00665	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—SLC5A5—ovarian cancer	0.000679	0.00662	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	0.000677	0.00659	CbGpPWpGaD
Ezogabine—CYP2A6—Oxidation by Cytochrome P450—CYP1B1—ovarian cancer	0.000674	0.00656	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—NME2—ovarian cancer	0.000668	0.00651	CbGpPWpGaD
Ezogabine—Asthenia—Doxorubicin—ovarian cancer	0.000666	0.000753	CcSEcCtD
Ezogabine—UGT1A4—Biological oxidations—CYP1B1—ovarian cancer	0.000664	0.00647	CbGpPWpGaD
Ezogabine—Dizziness—Epirubicin—ovarian cancer	0.000663	0.00075	CcSEcCtD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	0.000662	0.00645	CbGpPWpGaD
Ezogabine—UGT1A3—NRF2 pathway—SLC2A1—ovarian cancer	0.000656	0.00639	CbGpPWpGaD
Ezogabine—UGT1A4—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000655	0.00638	CbGpPWpGaD
Ezogabine—Rash—Epirubicin—ovarian cancer	0.000632	0.000715	CcSEcCtD
Ezogabine—Dermatitis—Epirubicin—ovarian cancer	0.000632	0.000714	CcSEcCtD
Ezogabine—Dizziness—Doxorubicin—ovarian cancer	0.000614	0.000694	CcSEcCtD
Ezogabine—UGT1A4—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	0.000609	0.00594	CbGpPWpGaD
Ezogabine—Nausea—Epirubicin—ovarian cancer	0.000596	0.000673	CcSEcCtD
Ezogabine—Rash—Doxorubicin—ovarian cancer	0.000585	0.000661	CcSEcCtD
Ezogabine—Dermatitis—Doxorubicin—ovarian cancer	0.000585	0.000661	CcSEcCtD
Ezogabine—CYP2A6—vagina—ovarian cancer	0.000574	0.0455	CbGeAlD
Ezogabine—UGT1A9—PPAR Alpha Pathway—MYC—ovarian cancer	0.000565	0.0055	CbGpPWpGaD
Ezogabine—CYP2A6—Phase 1 - Functionalization of compounds—CYP1B1—ovarian cancer	0.000553	0.00539	CbGpPWpGaD
Ezogabine—UGT1A3—Biological oxidations—CYP1B1—ovarian cancer	0.000552	0.00538	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—MAPK3—ovarian cancer	0.000552	0.00537	CbGpPWpGaD
Ezogabine—KCNQ3—L1CAM interactions—MAPK3—ovarian cancer	0.000552	0.00537	CbGpPWpGaD
Ezogabine—Nausea—Doxorubicin—ovarian cancer	0.000551	0.000623	CcSEcCtD
Ezogabine—UGT1A3—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000544	0.0053	CbGpPWpGaD
Ezogabine—KCNQ3—L1CAM interactions—MAPK1—ovarian cancer	0.000525	0.00511	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—MAPK1—ovarian cancer	0.000525	0.00511	CbGpPWpGaD
Ezogabine—KCNQ2—L1CAM interactions—EGFR—ovarian cancer	0.000525	0.00511	CbGpPWpGaD
Ezogabine—KCNQ3—L1CAM interactions—EGFR—ovarian cancer	0.000525	0.00511	CbGpPWpGaD
Ezogabine—UGT1A3—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	0.000506	0.00493	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—YAP1—ovarian cancer	0.000495	0.00482	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—SLC5A5—ovarian cancer	0.000469	0.00457	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SLC5A5—ovarian cancer	0.000469	0.00457	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	0.000467	0.00455	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—CDKN1B—ovarian cancer	0.000467	0.00455	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	0.000457	0.00446	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—IL2—ovarian cancer	0.000457	0.00446	CbGpPWpGaD
Ezogabine—UGT1A1—NRF2 pathway—SLC2A1—ovarian cancer	0.000453	0.00442	CbGpPWpGaD
Ezogabine—UGT1A9—NRF2 pathway—SLC2A1—ovarian cancer	0.000453	0.00442	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CYTB—ovarian cancer	0.00043	0.00419	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—MAPK1—ovarian cancer	0.000414	0.00403	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—MAPK1—ovarian cancer	0.000414	0.00403	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—NME2—ovarian cancer	0.000405	0.00394	CbGpPWpGaD
Ezogabine—UGT1A9—Fatty acid, triacylglycerol, and ketone body metabolism—FASN—ovarian cancer	0.000404	0.00393	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MET—ovarian cancer	0.000391	0.00381	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MET—ovarian cancer	0.000391	0.00381	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—IL6ST—ovarian cancer	0.000383	0.00374	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—IL6ST—ovarian cancer	0.000383	0.00374	CbGpPWpGaD
Ezogabine—UGT1A1—Biological oxidations—CYP1B1—ovarian cancer	0.000381	0.00372	CbGpPWpGaD
Ezogabine—UGT1A9—Biological oxidations—CYP1B1—ovarian cancer	0.000381	0.00372	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PPP1CC—ovarian cancer	0.000376	0.00367	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—BRIP1—ovarian cancer	0.000376	0.00367	CbGpPWpGaD
Ezogabine—UGT1A1—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000376	0.00366	CbGpPWpGaD
Ezogabine—UGT1A9—Metapathway biotransformation—CYP1B1—ovarian cancer	0.000376	0.00366	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—SLC5A5—ovarian cancer	0.000362	0.00353	CbGpPWpGaD
Ezogabine—UGT1A1—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	0.00035	0.00341	CbGpPWpGaD
Ezogabine—UGT1A9—Aryl Hydrocarbon Receptor Pathway—EGFR—ovarian cancer	0.00035	0.00341	CbGpPWpGaD
Ezogabine—CYP2A6—NRF2 pathway—SLC2A1—ovarian cancer	0.00035	0.00341	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—NME2—ovarian cancer	0.000336	0.00328	CbGpPWpGaD
Ezogabine—KCNQ5—Neuronal System—HRAS—ovarian cancer	0.000332	0.00324	CbGpPWpGaD
Ezogabine—KCNQ4—Neuronal System—HRAS—ovarian cancer	0.000332	0.00324	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MMP2—ovarian cancer	0.000327	0.00318	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP2—ovarian cancer	0.000327	0.00318	CbGpPWpGaD
Ezogabine—CYP2A6—Fluoropyrimidine Activity—TP53—ovarian cancer	0.000295	0.00288	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PPP1CC—ovarian cancer	0.000294	0.00286	CbGpPWpGaD
Ezogabine—CYP2A6—Biological oxidations—CYP1B1—ovarian cancer	0.000294	0.00286	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—ERBB2—ovarian cancer	0.000286	0.00279	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—ERBB2—ovarian cancer	0.000286	0.00279	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MET—ovarian cancer	0.000279	0.00272	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MET—ovarian cancer	0.000279	0.00272	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—IL6ST—ovarian cancer	0.000274	0.00267	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—IL6ST—ovarian cancer	0.000274	0.00267	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYTB—ovarian cancer	0.000261	0.00254	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—YAP1—ovarian cancer	0.000252	0.00246	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MMP9—ovarian cancer	0.000245	0.00239	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MMP9—ovarian cancer	0.000245	0.00239	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MMP2—ovarian cancer	0.000233	0.00227	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP2—ovarian cancer	0.000233	0.00227	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—NME2—ovarian cancer	0.000232	0.00227	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—NME2—ovarian cancer	0.000232	0.00227	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PPP1CC—ovarian cancer	0.000228	0.00222	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—BRIP1—ovarian cancer	0.000228	0.00222	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—MAPK1—ovarian cancer	0.000224	0.00218	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—MAPK1—ovarian cancer	0.000224	0.00218	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—VEGFA—ovarian cancer	0.00022	0.00215	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—VEGFA—ovarian cancer	0.00022	0.00215	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—NRAS—ovarian cancer	0.000218	0.00212	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—NRAS—ovarian cancer	0.000218	0.00212	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYTB—ovarian cancer	0.000217	0.00211	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MAPK3—ovarian cancer	0.000208	0.00203	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MAPK3—ovarian cancer	0.000208	0.00203	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—FASN—ovarian cancer	0.000206	0.002	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—ERBB2—ovarian cancer	0.000204	0.00199	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—ERBB2—ovarian cancer	0.000204	0.00199	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—SLC5A5—ovarian cancer	0.000202	0.00197	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—MAPK1—ovarian cancer	0.000198	0.00193	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—MAPK1—ovarian cancer	0.000198	0.00193	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—EGFR—ovarian cancer	0.000198	0.00193	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—EGFR—ovarian cancer	0.000198	0.00193	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—YAP1—ovarian cancer	0.000197	0.00192	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—SLC2A1—ovarian cancer	0.000195	0.0019	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PPP1CC—ovarian cancer	0.00019	0.00185	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—BRIP1—ovarian cancer	0.00019	0.00185	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CYP1B1—ovarian cancer	0.000187	0.00183	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—KRAS—ovarian cancer	0.000187	0.00183	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—KRAS—ovarian cancer	0.000187	0.00183	CbGpPWpGaD
Ezogabine—KCNQ2—Neuronal System—HRAS—ovarian cancer	0.000179	0.00175	CbGpPWpGaD
Ezogabine—KCNQ3—Neuronal System—HRAS—ovarian cancer	0.000179	0.00175	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—NME2—ovarian cancer	0.000179	0.00175	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—CTNNB1—ovarian cancer	0.000179	0.00174	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—CTNNB1—ovarian cancer	0.000179	0.00174	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MMP9—ovarian cancer	0.000175	0.00171	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MMP9—ovarian cancer	0.000175	0.00171	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PPP2R1A—ovarian cancer	0.000166	0.00162	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—FASN—ovarian cancer	0.000161	0.00157	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—HRAS—ovarian cancer	0.000159	0.00155	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—HRAS—ovarian cancer	0.000159	0.00155	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—VEGFA—ovarian cancer	0.000157	0.00153	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—VEGFA—ovarian cancer	0.000157	0.00153	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—STAT3—ovarian cancer	0.000156	0.00152	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—STAT3—ovarian cancer	0.000156	0.00152	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—NRAS—ovarian cancer	0.000155	0.00151	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—NRAS—ovarian cancer	0.000155	0.00151	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—ABCB1—ovarian cancer	0.000154	0.0015	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—YAP1—ovarian cancer	0.000153	0.00149	CbGpPWpGaD
Ezogabine—KCNQ2—Axon guidance—IL6—ovarian cancer	0.000152	0.00149	CbGpPWpGaD
Ezogabine—KCNQ3—Axon guidance—IL6—ovarian cancer	0.000152	0.00149	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—TYMS—ovarian cancer	0.000152	0.00148	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYTB—ovarian cancer	0.00015	0.00146	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYTB—ovarian cancer	0.00015	0.00146	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MAPK3—ovarian cancer	0.000149	0.00145	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MAPK3—ovarian cancer	0.000149	0.00145	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CYP1B1—ovarian cancer	0.000146	0.00143	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—MAPK1—ovarian cancer	0.000142	0.00138	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—MAPK1—ovarian cancer	0.000142	0.00138	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—EGFR—ovarian cancer	0.000142	0.00138	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—EGFR—ovarian cancer	0.000142	0.00138	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—KRAS—ovarian cancer	0.000134	0.0013	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—KRAS—ovarian cancer	0.000134	0.0013	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—BRIP1—ovarian cancer	0.000131	0.00128	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PPP1CC—ovarian cancer	0.000131	0.00128	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—BRIP1—ovarian cancer	0.000131	0.00128	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PPP1CC—ovarian cancer	0.000131	0.00128	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—YAP1—ovarian cancer	0.000127	0.00124	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—FASN—ovarian cancer	0.000125	0.00121	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—SLC5A5—ovarian cancer	0.000123	0.00119	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—CAV1—ovarian cancer	0.000122	0.00119	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—SLC2A1—ovarian cancer	0.000118	0.00115	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYTB—ovarian cancer	0.000115	0.00113	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—HRAS—ovarian cancer	0.000114	0.00111	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—HRAS—ovarian cancer	0.000114	0.00111	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CYP1B1—ovarian cancer	0.000114	0.00111	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CG—ovarian cancer	0.000111	0.00108	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—IL6—ovarian cancer	0.000109	0.00106	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—IL6—ovarian cancer	0.000109	0.00106	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—FASN—ovarian cancer	0.000104	0.00101	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SLC5A5—ovarian cancer	0.000102	0.000993	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PPP1CC—ovarian cancer	0.000101	0.000983	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—BRIP1—ovarian cancer	0.000101	0.000983	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PPP2R1A—ovarian cancer	0.000101	0.000981	CbGpPWpGaD
Ezogabine—KCNQ2—Developmental Biology—AKT1—ovarian cancer	0.0001	0.000978	CbGpPWpGaD
Ezogabine—KCNQ3—Developmental Biology—AKT1—ovarian cancer	0.0001	0.000978	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—SLC2A1—ovarian cancer	9.84e-05	0.000959	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CD—ovarian cancer	9.78e-05	0.000953	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—CAV1—ovarian cancer	9.54e-05	0.00093	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CYP1B1—ovarian cancer	9.44e-05	0.00092	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—ABCB1—ovarian cancer	9.35e-05	0.000911	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—TYMS—ovarian cancer	9.18e-05	0.000895	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—YAP1—ovarian cancer	8.78e-05	0.000856	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—YAP1—ovarian cancer	8.78e-05	0.000856	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CG—ovarian cancer	8.69e-05	0.000847	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CB—ovarian cancer	8.52e-05	0.00083	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PPP2R1A—ovarian cancer	8.37e-05	0.000816	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—ABCB1—ovarian cancer	7.77e-05	0.000757	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CD—ovarian cancer	7.64e-05	0.000744	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—TYMS—ovarian cancer	7.63e-05	0.000744	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—CAV1—ovarian cancer	7.4e-05	0.000721	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PTEN—ovarian cancer	7.36e-05	0.000718	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—FASN—ovarian cancer	7.16e-05	0.000698	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—FASN—ovarian cancer	7.16e-05	0.000698	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SLC5A5—ovarian cancer	7.04e-05	0.000686	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SLC5A5—ovarian cancer	7.04e-05	0.000686	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—SLC2A1—ovarian cancer	6.8e-05	0.000663	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—SLC2A1—ovarian cancer	6.8e-05	0.000663	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—YAP1—ovarian cancer	6.77e-05	0.00066	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CG—ovarian cancer	6.74e-05	0.000657	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CB—ovarian cancer	6.66e-05	0.000649	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CYP1B1—ovarian cancer	6.52e-05	0.000635	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CYP1B1—ovarian cancer	6.52e-05	0.000635	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—CAV1—ovarian cancer	6.15e-05	0.000599	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CD—ovarian cancer	5.92e-05	0.000577	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PPP2R1A—ovarian cancer	5.78e-05	0.000563	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PPP2R1A—ovarian cancer	5.78e-05	0.000563	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PTEN—ovarian cancer	5.75e-05	0.000561	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CG—ovarian cancer	5.6e-05	0.000546	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—FASN—ovarian cancer	5.52e-05	0.000538	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SLC5A5—ovarian cancer	5.43e-05	0.000529	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—ABCB1—ovarian cancer	5.37e-05	0.000523	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—ABCB1—ovarian cancer	5.37e-05	0.000523	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—TYMS—ovarian cancer	5.27e-05	0.000514	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—TYMS—ovarian cancer	5.27e-05	0.000514	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—SLC2A1—ovarian cancer	5.24e-05	0.000511	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—PIK3CA—ovarian cancer	5.2e-05	0.000506	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CB—ovarian cancer	5.16e-05	0.000503	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CYP1B1—ovarian cancer	5.03e-05	0.00049	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CD—ovarian cancer	4.92e-05	0.00048	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PTEN—ovarian cancer	4.46e-05	0.000435	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PPP2R1A—ovarian cancer	4.46e-05	0.000434	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CB—ovarian cancer	4.29e-05	0.000418	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—CAV1—ovarian cancer	4.25e-05	0.000414	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—CAV1—ovarian cancer	4.25e-05	0.000414	CbGpPWpGaD
Ezogabine—NAT2—Metabolism—AKT1—ovarian cancer	4.24e-05	0.000414	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—ABCB1—ovarian cancer	4.14e-05	0.000403	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—TYMS—ovarian cancer	4.07e-05	0.000396	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism of lipids and lipoproteins—PIK3CA—ovarian cancer	4.06e-05	0.000396	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CG—ovarian cancer	3.87e-05	0.000377	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CG—ovarian cancer	3.87e-05	0.000377	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PTEN—ovarian cancer	3.71e-05	0.000361	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CD—ovarian cancer	3.4e-05	0.000332	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CD—ovarian cancer	3.4e-05	0.000332	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—CAV1—ovarian cancer	3.28e-05	0.000319	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—PIK3CA—ovarian cancer	3.15e-05	0.000307	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CG—ovarian cancer	2.98e-05	0.000291	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CB—ovarian cancer	2.97e-05	0.000289	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CB—ovarian cancer	2.97e-05	0.000289	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CD—ovarian cancer	2.62e-05	0.000256	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—PIK3CA—ovarian cancer	2.62e-05	0.000255	CbGpPWpGaD
Ezogabine—UGT1A4—Metabolism—AKT1—ovarian cancer	2.57e-05	0.000251	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PTEN—ovarian cancer	2.56e-05	0.00025	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PTEN—ovarian cancer	2.56e-05	0.00025	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CB—ovarian cancer	2.29e-05	0.000223	CbGpPWpGaD
Ezogabine—UGT1A3—Metabolism—AKT1—ovarian cancer	2.14e-05	0.000208	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PTEN—ovarian cancer	1.98e-05	0.000192	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—PIK3CA—ovarian cancer	1.81e-05	0.000176	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—PIK3CA—ovarian cancer	1.81e-05	0.000176	CbGpPWpGaD
Ezogabine—UGT1A9—Metabolism—AKT1—ovarian cancer	1.48e-05	0.000144	CbGpPWpGaD
Ezogabine—UGT1A1—Metabolism—AKT1—ovarian cancer	1.48e-05	0.000144	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—PIK3CA—ovarian cancer	1.39e-05	0.000136	CbGpPWpGaD
Ezogabine—CYP2A6—Metabolism—AKT1—ovarian cancer	1.14e-05	0.000111	CbGpPWpGaD
